Literature DB >> 1323266

Phosphodiesterase inhibition and positive inotropy in failing human myocardium.

W Schmitz1, T Eschenhagen, U Mende, F U Müller, J Neumann, H Scholz.   

Abstract

Positive inotropic effects of phosphodiesterase inhibitors like 3-isobutyl-1-methylxanthine (IBMX), pimobendan, adibendan, milrinone, saterinone, and enoximone are greatly diminished in isolated heart muscle preparations from human failing myocardium as compared to nonfailing myocardium. This is accompanied by a reduced increase in cAMP content in intact isometrically contracting human trabeculae. With anion exchange chromatography four peaks of phosphodiesterase activities (PDE I-IV) could be separated from both nonfailing and failing human myocardium. Substrate specificity, Km, and Vmax were similar in nonfailing and failing myocardium. Furthermore, the PDE inhibitors investigated exhibited similar IC50-values in both tissues, indicating that the sensitivity of the enzymes from nonfailing and failing tissue was unchanged. Thus, changes in PDE are probably not responsible for the reduced positive inotropic and cAMP-increasing effects of PDE inhibitors in human failing heart muscle preparations. Instead, an increase in signal transducing inhibitory G-proteins may keep the adenylyl cyclase at reduced activity, resulting in an attenuated formation of cAMP, even in the presence of PDE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323266     DOI: 10.1007/978-3-642-72474-9_5

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  4 in total

1.  Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through beta(2)-adrenoceptors than the effects of (-)-noradrenaline through beta (1)-adrenoceptors in human atrial myocardium.

Authors:  T Christ; A Engel; U Ravens; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-15       Impact factor: 3.000

2.  The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells.

Authors:  Alberto Kaumann; Annalese B T Semmler; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-21       Impact factor: 3.000

Review 3.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

4.  Regulation of ICa,L and force by PDEs in human-induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Umber Saleem; Djemail Ismaili; Ingra Mannhardt; Hans Pinnschmidt; Thomas Schulze; Torsten Christ; Thomas Eschenhagen; Arne Hansen
Journal:  Br J Pharmacol       Date:  2020-03-31       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.